1. Synergistic therapeutics: Co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment
   Manasa Gangadhar Shetty et al, 2024, European Journal of Medicinal Chemistry CrossRef
2. From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: Synthesis and biological evaluation of valproic esters of 3′-C-methyladenosine
   Riccardo Petrelli et al, 2014, Bioorganic & Medicinal Chemistry Letters CrossRef
3. Semaphorin 4A Stabilizes Human Regulatory T Cell Phenotype via Plexin B1
   Svetlana P. Chapoval et al, 2019, ImmunoHorizons CrossRef
4. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
   Loredana Cappellacci et al, 2020, Current Medicinal Chemistry CrossRef
5. tert‐Butylcarbamate‐Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells
   Sergio Valente et al, 2013, ChemMedChem CrossRef